Carna Biosciences, Inc. (CBIXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Carna Biosciences, Inc. (CBIXF) trades at $10.75. Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Japan, focusing on kinase-targeted drug discovery. They develop therapies for unmet medical needs, offering kinase-related products and services. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CBIXF: CBIXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBIXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBIXF: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Carna Biosciences, Inc. (CBIXF) Healthcare & Pipeline Overview
Carna Biosciences, Inc., a Japanese clinical-stage biopharmaceutical company, specializes in kinase-targeted drug discovery for unmet medical needs. Their portfolio includes preclinical and Phase 1 assets targeting cancer and inflammatory disorders, complemented by kinase-related products and services, positioning them in a competitive biotechnology landscape.
What Is the Investment Thesis for CBIXF?
Carna Biosciences presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The company's value hinges on the successful development and commercialization of its drug pipeline, particularly AS-0871, currently in Phase 1 trials. Positive clinical trial data could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisitions. However, the company's negative profit margin of -375.0% indicates a heavy reliance on external funding and future revenue streams. The company's collaborations with established pharmaceutical companies offer validation of its technology and potential for future revenue. A key risk lies in the inherent uncertainty of drug development, with potential for clinical trial failures or regulatory hurdles. Investors should closely monitor clinical trial progress, partnership developments, and the company's cash runway.
Based on FMP financials and quantitative analysis
CBIXF Key Highlights
Carna Biosciences operates as a clinical-stage biopharmaceutical firm, indicating a focus on drug development rather than established product sales.
- The company's negative P/E ratio of -3.22 reflects its current lack of profitability, common for biotech companies investing heavily in R&D.
- A gross margin of 67.0% suggests strong potential profitability on its service offerings, if scaled effectively.
- The company's beta of 1.49 indicates higher volatility compared to the overall market, typical for biotech stocks.
- Carna Biosciences has established collaborations with Johnson & Johnson, Gilead, and others, validating its technology and providing potential revenue streams.
Who Are CBIXF's Competitors?
CBIXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AAPGV Ascentage Pharma Group International | $17.38 | +0.75% | $127M | 46 |
| ADOCY Adocia S.A. | $11.80 | +0.00% | $170M | 56 |
| AMGXF AnGes, Inc. | $0.36 | +0.00% | $143M | 59 |
| BRNHF Broncus Holding Corporation | $0.08 | +0.00% | $42.1M | 50 |
| EKDHF EKF Diagnostics Holdings plc | $0.34 | +0.00% | $146M | 40 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBIXF's Key Strengths?
Specialized expertise in kinase-targeted drug discovery.
- Proprietary library of kinase inhibitors.
- Established collaborations with major pharmaceutical companies.
- Pipeline of drug candidates in preclinical and clinical development.
What Are CBIXF's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies.
- Reliance on external funding and partnerships.
- High risk of clinical trial failures.
- Concentration on the Japanese market.
What Could Drive CBIXF Stock Higher?
Phase 1 clinical trial results for AS-0871 in inflammatory and immune disorders.
- Preclinical data releases for AS-0141 in cancer.
- Potential for new partnerships with pharmaceutical companies.
- Progress in the development of AS-1763 for chronic lymphocytic leukemia.
What Are the Key Risks for CBIXF?
Clinical trial failures for drug candidates.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies.
- Dependence on external funding and partnerships.
- Limited liquidity due to OTC market listing.
What Are the Growth Opportunities for CBIXF?
- Expansion of Kinase Inhibitor Pipeline: Carna Biosciences has the opportunity to expand its pipeline of kinase inhibitors targeting various diseases. The market for targeted therapies is growing, with a global market size estimated at billions of dollars. Successful development and commercialization of new kinase inhibitors could significantly increase revenue streams. This growth is contingent on positive preclinical and clinical trial results, as well as securing partnerships for late-stage development and commercialization. Timeline: Ongoing, with new compounds entering preclinical development annually.
- Strategic Partnerships and Licensing Agreements: Carna Biosciences can leverage its expertise in kinase biology to form strategic partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide funding, resources, and expertise to accelerate drug development and commercialization. The potential revenue from upfront payments, milestone payments, and royalties could be substantial. This strategy depends on the attractiveness of Carna Biosciences' technology and pipeline assets to potential partners. Timeline: Ongoing, with potential for new agreements in the next 1-3 years.
- Geographic Expansion Beyond Japan: Carna Biosciences can expand its geographic focus beyond Japan to target larger markets in North America and Europe. This expansion would require establishing a presence in these regions, either through direct investment or partnerships. The potential revenue from these markets is significant, but the expansion would also require substantial resources and expertise. Timeline: Medium-term, with potential for expansion in the next 3-5 years.
- Development of Companion Diagnostics: Carna Biosciences can develop companion diagnostics to identify patients who are most likely to respond to its kinase inhibitors. This approach can improve clinical trial outcomes, increase the likelihood of regulatory approval, and enhance the commercial value of its drugs. The market for companion diagnostics is growing, driven by the increasing focus on personalized medicine. Timeline: Ongoing, with potential for diagnostic development alongside clinical trials.
- Expansion of Service Offerings: Carna Biosciences can expand its service offerings related to kinase biology, such as profiling, assay development, and protein production. These services can generate revenue and provide valuable insights into kinase biology that can be used to support its drug discovery efforts. The market for these services is growing, driven by the increasing demand for kinase-related research tools and services. Timeline: Ongoing, with potential for expansion in the next 1-2 years.
What Threats Does CBIXF Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
What Are CBIXF's Competitive Advantages?
- Specialized expertise in kinase biology and drug discovery.
- Proprietary library of kinase inhibitors.
- Established collaborations with major pharmaceutical companies.
- Pipeline of drug candidates in preclinical and clinical development.
What Does CBIXF Do?
Founded in 2003 and headquartered in Kobe, Japan, Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative drug therapies. The company addresses unmet medical needs, primarily within the Japanese market. Carna Biosciences' initial focus was on providing research tools and services related to kinases, a family of enzymes critical in cell signaling. Their offerings include kinase proteins, substrates, assay kits, stable cell lines, and biotinylated kinases, which are utilized in studying kinase-molecule interactions. They also provide various services such as profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, along with custom protein production for crystallography. Over time, Carna Biosciences has expanded its focus to include the development of its own therapeutic pipeline. Their drug development programs target various diseases, including cancer, inflammatory disorders, and B cell malignancies. Key pipeline assets include AS-0141, an oral CDC7 kinase inhibitor in preclinical development for cancer; AS-0871, a small molecule drug in Phase 1 clinical trials for inflammatory and immune disorders; and AS-1763, an oral inhibitor targeting chronic lymphocytic leukemia and other B cell malignancies, currently in preclinical trials. Carna Biosciences has established collaborations with several pharmaceutical companies, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals, to support its research and development efforts.
What Products and Services Does CBIXF Offer?
- Discovers and develops drug therapies for unmet medical needs.
- Focuses on kinase-targeted drug discovery.
- Offers kinase proteins, substrates, and assay kits.
- Provides profiling and assay services.
- Develops orally bioavailable small molecule inhibitors.
- Conducts preclinical and clinical trials.
- Collaborates with pharmaceutical companies for research and development.
How Does CBIXF Make Money?
- Develops and out-licenses drug candidates to larger pharmaceutical companies.
- Generates revenue through research collaborations and service offerings.
- Focuses on developing kinase inhibitors for various diseases.
- Funds research and development through partnerships and potential future product sales.
What Industry Does CBIXF Operate In?
Carna Biosciences operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high failure rates. The market for kinase inhibitors is substantial, driven by the role of kinases in various diseases, particularly cancer and inflammatory disorders. The company competes with both large pharmaceutical companies and smaller biotech firms, facing challenges in securing funding, attracting talent, and navigating the complex regulatory landscape. Success in this industry requires innovative science, strong execution, and strategic partnerships. The biotechnology industry is experiencing growth due to advancements in genomics, proteomics, and personalized medicine.
Who Are CBIXF's Key Customers?
- Pharmaceutical companies seeking novel drug targets and candidates.
- Research institutions conducting kinase-related research.
- Biotech companies looking for research tools and services.
- Patients who may benefit from new kinase inhibitor therapies.
Company Profile
Carna Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kobe, JP. The company is led by CEO Kohichiro Yoshino. CBIXF has traded publicly since 2019.
Key Financial Metrics
Return on assets is -98.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 16.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.3%, the inverse of the P/E and a quick read on earnings relative to price.
CBIXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, which can be a strong indicator of potential growth.
- Community sentiment has been increasingly positive, with discussions highlighting the innovative therapies Carna is developing.
- The recent partnerships announced by Carna indicate a strategic direction that could enhance its market presence and drive revenue.
- Market perception is shifting favorably as the biotech sector shows resilience, and Carna's unique offerings are gaining attention.
Bear Case
- Some analysts express caution regarding the competitive landscape in the biotech industry, which can impact Carna's market share.
- Recent social sentiment has shown volatility, with mixed opinions among traders about the sustainability of Carna's growth trajectory.
- Concerns about regulatory hurdles in the biotech sector could pose risks to Carna's development timelines and product approvals.
- The overall market environment remains uncertain, with broader economic factors potentially affecting investor confidence in smaller biotech firms.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CBIXF Latest News
No recent news available for CBIXF.
CBIXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIXF.
Price Targets
Wall Street price target analysis for CBIXF.
CBIXF MoonshotScore
What does this score mean?
The MoonshotScore rates CBIXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kohichiro Yoshino
CEO
Kohichiro Yoshino is the CEO of Carna Biosciences, Inc. His background includes experience in the pharmaceutical and biotechnology industries. While specific details regarding his education and previous roles are not available in the provided data, his leadership is crucial for guiding Carna Biosciences' strategic direction and overseeing its research and development activities. He manages a team of 64 employees.
Track Record: Kohichiro Yoshino's track record at Carna Biosciences is reflected in the company's progress in developing its pipeline of kinase inhibitors and establishing collaborations with major pharmaceutical companies. The advancement of AS-0871 into Phase 1 clinical trials and the ongoing preclinical development of AS-0141 and AS-1763 are key milestones under his leadership. However, specific details on financial performance and strategic decisions driven by him are not available in the provided data.
CBIXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Carna Biosciences may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial reporting, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and disclosures (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Established collaborations with reputable pharmaceutical companies.
- Advancement of drug candidates into clinical trials.
- Presence of a scientific advisory board or experienced management team.
- Focus on a specific therapeutic area with unmet medical needs.
- Years in operation since 2003.
Common Questions About CBIXF (Healthcare)
What does Carna Biosciences, Inc. do?
Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing kinase-targeted therapies. They provide kinase-related research tools and services, and are advancing a pipeline of drug candidates targeting cancer, inflammatory disorders, and B cell malignancies. Their business model involves developing and out-licensing drug candidates, generating revenue through research collaborations, and focusing on unmet medical needs in Japan and beyond.
What are the main risks for CBIXF?
The main risks for Carna Biosciences, Inc. include the potential for clinical trial failures, regulatory hurdles in drug approval, competition from larger pharmaceutical companies, and dependence on external funding. As an OTC-listed company, CBIXF also faces risks related to limited liquidity and transparency. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for CBIXF?
Evaluate CBIXF on fundamentals, analyst consensus, and risk factors. Carna Biosciences presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. Not financial advice.
How frequently does CBIXF data refresh on this page?
CBIXF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBIXF's recent stock price performance?
Carna Biosciences, Inc. (CBIXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in kinase-targeted drug discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBIXF overvalued or undervalued right now?
Carna Biosciences, Inc. (CBIXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CBIXF before investing?
Before investing in Carna Biosciences, Inc. (CBIXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBIXF to a portfolio?
Key strength of Carna Biosciences, Inc. (CBIXF): Specialized expertise in kinase-targeted drug discovery. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.